<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT / ARTICLES</th>
<th>TITLE, AUTHORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00–08:45</td>
<td><strong>MEET THE PROFESSOR</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(6 parallel sessions)</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>NEW RESPONSE CRITERIA FOR LYMPHOMAS IN CLINICAL TRIALS (room A)</td>
<td>B.D. Cheson (Washington, USA)</td>
</tr>
<tr>
<td>IX</td>
<td>NEW TARGETS FOR LYMPOMA TREATMENT (room B I)</td>
<td>P.W.M. Johnson (Southampton, GB)</td>
</tr>
<tr>
<td>III</td>
<td>MICRNORNAS AND LYMPHOMAS (room B II)</td>
<td>C.M. Croce (Columbus, USA)</td>
</tr>
<tr>
<td>I</td>
<td>AUTO-IMMUNE DISORDERS AND LYMPOMA (room C)</td>
<td>F. Caligaris-Cappio (Milan, IT)</td>
</tr>
<tr>
<td>VIII</td>
<td>MAINTENANCE TREATMENT IN MULTIPLE MYELOMA (room E)</td>
<td>J.-L. Harousseau, (Nantes, FR)</td>
</tr>
<tr>
<td>VI</td>
<td>RADIOTherapy in non-Hodgkin lymphomas (Marquee Parco Ciani)</td>
<td>M. Gospodarowicz (Toronto, CA)</td>
</tr>
<tr>
<td>09:00–09:45</td>
<td><strong>MEET THE PROFESSOR</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(6 parallel sessions)</td>
<td></td>
</tr>
<tr>
<td>XIV</td>
<td>UPDATE ON T-CELL LYMOPHOMA (room A)</td>
<td>J.M. Vose (Omaha, USA)</td>
</tr>
<tr>
<td>XV</td>
<td>EXTRANODAL LYMPHOMA: A REAPPRAISAL (room B I)</td>
<td>E. Zucca (Bellinzona, CH)</td>
</tr>
<tr>
<td>XII</td>
<td>BURKITT LYMPHOMA VERSUS diffuse large B-CELL LYMPHOMA (room B II)</td>
<td>A. Rosenwald et al (Würzburg, DE)</td>
</tr>
<tr>
<td>XIII</td>
<td>NON-MALT MARGINAL ZONE LYMPHOMAS (room C)</td>
<td>C. Thieblemont (Paris, FR)</td>
</tr>
<tr>
<td>V</td>
<td>TREATMENT OF LYMPHOCYTE PREDOMINANT HODGKIN LYMPOMA (room E)</td>
<td>A. Engert (Cologne, DE)</td>
</tr>
<tr>
<td>X</td>
<td>NEW MONOClonal ANTIBODIES FOR NON-HODGKIN’S LYMPOMA (Marquee Parco Ciani)</td>
<td>J.P. Leonard et al (New York, USA)</td>
</tr>
<tr>
<td>10:00–10:45</td>
<td><strong>MEET THE PROFESSOR</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(6 parallel sessions)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>CURRENT TREATMENT STANDARDS AND future strategies in mantle cell lymphoma (room A)</td>
<td>M. Dreyling et al (Münich, DE)</td>
</tr>
<tr>
<td>IX</td>
<td>NEW TARGETS FOR LYMPOMA TREATMENT (room B I)</td>
<td>P.W.M. Johnson (Southampton, GB)</td>
</tr>
<tr>
<td>III</td>
<td>MICRNORNAS AND LYMPHOMAS (room B II)</td>
<td>C.M. Croce (Columbus, USA)</td>
</tr>
<tr>
<td>I</td>
<td>AUTO-IMMUNE DISORDERS AND LYMPOMA (room C)</td>
<td>F. Caligaris-Cappio (Milan, IT)</td>
</tr>
<tr>
<td>VIII</td>
<td>MAINTENANCE TREATMENT IN MULTIPLE MYELOMA (room E)</td>
<td>J.-L. Harousseau, (Nantes, FR)</td>
</tr>
<tr>
<td>II</td>
<td>NEW RESPONSE CRITERIA FOR LYMPOMAS IN CLINICAL TRIALS (Marquee Parco Ciani)</td>
<td>B.D. Cheson (Washington, USA)</td>
</tr>
<tr>
<td>11:00–12:00</td>
<td><strong>CONTOVERSY I: DO WE NEED RADIOTHERAPY IN EARLY HL?</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(room A, B, Marquee Parco Ciani)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: G.P. Canellos (Boston, USA)</td>
<td></td>
</tr>
<tr>
<td>064 - 005</td>
<td>PROS: J. Yehalom (New York, USA) vs COS: J.M. Connors (Vancouver, CA)</td>
<td></td>
</tr>
<tr>
<td>12:00–13:00</td>
<td><strong>LUNCH TIME</strong></td>
<td>Marquee Parco Ciani</td>
</tr>
<tr>
<td>13:00–14:30</td>
<td>OPENING OF THE CONFERENCE (room A, B, Marquee Parco Ciani)</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>WELCOME AND INTRODUCTORY REMARKS</td>
<td>F. Cavalli (Bellinzona, CH)</td>
</tr>
<tr>
<td>13:10</td>
<td><strong>AWARD OF THE SAN SALVATORE FOUNDATION</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>combined with Henry Kaplan Memorial Lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction to the Foundation: G. Ghiringhelli (Bellinzona, CH), President of the</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Presentation of the Award: R.A. Stahel (Zurich, CH), Chairman of the Scientific Committee</td>
<td></td>
</tr>
</tbody>
</table>
13:20  001  HENRY KAPLAN MEMORIAL LECTURE
DIFFUSE LARGE B-CELL LYMPHOMA: WHICH TREATMENT FOR PATIENTS WHO FAILED FIRST LINE TREATMENT?
B. Coiffier (Pierre Bénite, FR)

13:50  002  SPECIAL EVENT: “10 YEARS OF MONOCLONAL ANTIBODIES”
With the participation of Kaplan Lecture awardees since 1984: Robert Gallo, USA (1984); Vincent DeVita, USA (1990); Gianni Bonadonna, IT (1993); James O. Armitage, USA (1996); Peter Isaacson, GB (1999); Volker Diehl, DE (2002); George P. Canellos, USA (2005); Bertrand Coiffier, FR (2008).
Co-chair: T.A. Lister (London, GB) and R.I. Fisher (Rochester, USA)
*organized on an unrestricted grant from F. Hoffmann-La Roche Ltd

14:30–15:35
SESSION 1 – 50th ANNIVERSARY OF BURKITT LYMPHOMA (room A, B, Marquee Parco Ciani)
Co-chairs: A. Reiter (Giessen, DE) and H. Stein (Berlin, DE)

14:30  006  50th ANNIVERSARY OF DISCOVERY OF BURKITT LYMPHOMA: HISTORY AND BIOLOGY
I.T. Magrath (Brussels, BE)

14:50  007  CONSERVED ONCOGENIC MODULE ACTIVATION PATTERNS (COMAPS) IDENTIFY BIOLOGICALLY HOMOGENEOUS GROUPS OF DIFFUSE LARGE B-CELL LYMPHOMAS AND CLEARLY DEFINE BURKITT LYMPHOMA
S. Bentink et al (Regensburg, DE)

15:05  008  RECENT RESULTS IN THE TREATMENT OF BURKITT LYMPHOMA
D. Hoelzer (Frankfurt, DE)

15:20  009  A PROSPECTIVE STUDY OF DOSE-ADJUSTED (DA) EPOCH WITH RITUXIMAB IN ADULTS WITH NEWLY DIAGNOSED BURKITT LYMPHOMA: A REGIMEN WITH HIGH EFFICACY AND LOW TOXICITY
K. Dunleavy et al (Bethesda, USA)

15:35–16:00  COFFEE BREAK (Marquee Parco Ciani)

16:00–17:15
SESSION 2 – MANTLE CELL LYMPHOMA (room A, B, Marquee Parco Ciani)
Co-chairs: M.F. Fey (Bern, CH) and W. Hiddemann (Munich, DE)

16:00  010  GENOMIC HYPERMETHYLATION CHARACTERIZES AN AGGRESSIVE SUBSET OF MANTLE CELL LYMPHOMA
T. Greiner et al (Omaha, USA)

16:15  011  INITIAL OBSERVATION WITHOUT THERAPY IN PATIENTS WITH ASYMPTOMATIC, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA (MCL)
P. Martin et al (New York, USA)

16:30  012  IMMUNOCHEMOTHERAPY (R-MCP) IN ADVANCED MANTLE CELL LYMPHOMA IS NOT SUPERIOR TO CHEMOTHERAPY (MCP) ALONE - 50 MONTHS UP DATE OF THE OSHO PHASE III STUDY (OSHO#39)
M. Herold et al (Erfurt, DE)

16:45  013  RESULTS OF SEQUENTIAL CHEMOTHERAPY FOLLOWED BY HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL RESCUE FOR MANTLE CELL LYMPHOMA: ROLE OF RITUXIMAB AND FUNCTIONAL IMAGING
A.D. Zelenetz et al (New York, USA)

17:00  014  NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION (NST) VS. AUTOLOGOUS TRANSPLANTATION (ASCT) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)
I.E. Khouri et al (Houston, USA)

17:30–18:30  “FOCUS ON…” SESSIONS (5 parallel sessions):

17:30–18:30  RADIOIMMUNOTHERAPY (room A)
Chair: D.G. Maloney (Seattle, USA)

17:30  015  RADIOIMMUNOTHERAPY FOR INDOLENT NON HODGKIN LYMPHOMA WITH 131I-RITUXIMAB IN CLINICAL PRACTICE: 8 YEAR SINGLE INSTITUTION EXPERIENCE OF 129 CONSECUTIVE PATIENTS
M.F. Leahy et al (Fremantle, AU)

17:40  016  OUTCOME OF 87 PREVIOUSLY UNTREATED INDOLENT NON-HODGKIN'S LYMPHOMA PATIENTS TREATED WITH FLUDARABINE AND MITOXANTRONE CHEMOTHERAPY FOLLOWED BY 90Y IBRUTIMOMAB TIUXETAN
P. Zinzani et al (Bologna, IT)

17:50  017  YTTRIUM-90 IBRUTIMOMAB TIUXETAN (90Y-ZEVALIN) COMBINED WITH THE NOVEL EXPANDED PORPHYRIN MOTEXAFIN GADOLINIUM (MGD, XCYTRIN) PRODUCES RAPID AND SUSTAINED COMPLETE REMISSIONS (CR) IN PATIENTS WITH RITUXIMAB-REFRACTORY FOLLICULAR LYMPHOMA: FINAL RESULTS OF A PHASE I/II CLINICAL TRIAL
A.M. Evens et al (Chicago, USA)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00</td>
<td>018</td>
<td>YTTRIUM-90-LABELED IBRITUMOMAB TIUXETAN (ZEVALIN®) FOR PRIMARY CNS LYMPHOMA – FINAL RESULTS OF A PHASE II STUDY</td>
<td>P. Kiewe et al (Berlin, DE)</td>
</tr>
<tr>
<td>18:10</td>
<td>019</td>
<td>PHASE I/II STUDY OF YTTRIUM-90 LABELED HUMANIZED ANTI-TAC (HAT) MONOCLONAL ANTIBODY AND CALCIUM DTPA IN CD25-EXPRESSING MALIGNANCIES OTHER THAN ADULT T-CELL LEUKEMIA</td>
<td>D. O'Mahony et al (Bethesda, USA)</td>
</tr>
<tr>
<td>18:20</td>
<td>020</td>
<td>RADIOIMMUNOTHERAPY IN NHL AT HIGH CUMULATIVE DOSES OF 90Y WITH FRACTIONATED DOSES OF DOTA-CONJUGATED HUMANIZED ANTI-CD22 IGG, EFRATUZUMAB</td>
<td>F. Morschhauser et al (Lille, FR)</td>
</tr>
<tr>
<td>18:30</td>
<td>021</td>
<td>POLYMORPHISMS IN APOPTOSIS AND IMMUNOREGULATORY RELATED GENES ARE ASSOCIATED WITH AN INCREASED RISK OF CHRONIC LYMPHOCYTIC LEUKEMIA</td>
<td>A. Enjuanes et al (Barcelona, ES)</td>
</tr>
<tr>
<td>18:40</td>
<td>022</td>
<td>DOUBLING TIME OF SOLUBLE CD23 (SCD23DT): A POWERFUL INDEPENDENT PROGNOSTIC FACTOR FOR STAGE AN UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS</td>
<td>N. Meuleman et al (Bruxelles, BE)</td>
</tr>
<tr>
<td>18:50</td>
<td>023</td>
<td>QUANTITATIVE GENE EXPRESSION ANALYSIS OF SURROGATE MARKERS FOR GENETIC RISK GROUPS AND SURVIVAL IN CLL</td>
<td>D. Kienle et al (Ulm, DE)</td>
</tr>
<tr>
<td>19:00</td>
<td>024</td>
<td>B CELL RECEPTOR-DEPENDENT INDUCTION OF CCL3 AND CCL4 BY CHRONIC LYMPHOCYTIC LEUKEMIA B CELLS IS ASSOCIATED WITH ZAP-70 AND INDEPENDENT OF SYC INHIBITION</td>
<td>J.A. Burger et al (Houston, USA)</td>
</tr>
<tr>
<td>19:10</td>
<td>025</td>
<td>ABNORMAL SERUM FREE LIGHT CHAIN RATIOS ARE ASSOCIATED WITH POOR SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA</td>
<td>G. Mead et al (Birmingham, GB)</td>
</tr>
<tr>
<td>19:20</td>
<td>026</td>
<td>CLINICAL CASPASE ACTIVATION IN CLL BY GCS-100, A NOVEL CARBOHYDRATE, IN A PHASE 2 STUDY</td>
<td>F.E. Cotter et al (London, GB)</td>
</tr>
</tbody>
</table>

**17:30–18:30 CLL (room B)**

**Chair:** M.J. Keating (Houston, USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>021</td>
<td>POLYMORPHISMS IN APOPTOSIS AND IMMUNOREGULATORY RELATED GENES ARE ASSOCIATED WITH AN INCREASED RISK OF CHRONIC LYMPHOCYTIC LEUKEMIA</td>
<td>A. Enjuanes et al (Barcelona, ES)</td>
</tr>
<tr>
<td>17:40</td>
<td>022</td>
<td>DOUBLING TIME OF SOLUBLE CD23 (SCD23DT): A POWERFUL INDEPENDENT PROGNOSTIC FACTOR FOR STAGE AN UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS</td>
<td>N. Meuleman et al (Bruxelles, BE)</td>
</tr>
<tr>
<td>17:50</td>
<td>023</td>
<td>QUANTITATIVE GENE EXPRESSION ANALYSIS OF SURROGATE MARKERS FOR GENETIC RISK GROUPS AND SURVIVAL IN CLL</td>
<td>D. Kienle et al (Ulm, DE)</td>
</tr>
</tbody>
</table>

**17:30–18:30 TRANSPLANTATION (room C)**

**Chair:** J.-L. Harousseau (Nantes, FR)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>027</td>
<td>THE GICAT (ITALIAN COOPERATIVE GROUP ON AIDS AND TUMORS) EXPERIENCE WITH HIGH DOSE THERAPY AND PERIPHERAL BLOOD STEM CELL TRANSPLANTATION AS SALVAGE TREATMENT FOR HIV-RELATED LYMPHOMA: LONG-TERM RESULTS AND MULTIVARIATE ANALYSIS FOR PROGNOSTIC FACTORS</td>
<td>A. Re et al (Brescia, IT)</td>
</tr>
<tr>
<td>17:40</td>
<td>028</td>
<td>EVALUATION OF MYELOABLATIVE THERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST REMISSION IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA AFTER INITIAL COMBINED IMMUNO-CHEMOTHERAPY (R-CHOP) AND CONVENTIONAL CHEMOTHERAPY (CHOP): ANALYSIS OF 540 PATIENTS TREATED IN PROSPECTIVE RANDOMIZED TRIALS OF THE GERMAN LOW GRADE LYMPHOMA STUDY GROUP (GLSG)</td>
<td>Ch. Buske et al (Munich, DE)</td>
</tr>
<tr>
<td>17:50</td>
<td>029</td>
<td>MYELOABLATIVE THERAPY FOR RECURRENT HODGKIN LYMPHOMA: GOOD SUCCESS RATES IRRESPECTIVE OF PREVIOUS TREATMENTS IN THE UKLG LYG09 TRIAL (ISRCTN97144519)</td>
<td>P.W.M. Johnson et al (Southampton, GB)</td>
</tr>
<tr>
<td>18:00</td>
<td>030</td>
<td>ALLOGENEIC STEM CELL TRANSPLANTATION IN MATURE T-CELL LYMPHOMA – AN ENCOURAGING ALTERNATIVE</td>
<td>M. Nickelsen et al (Hamburg, DE)</td>
</tr>
<tr>
<td>18:10</td>
<td>031</td>
<td>GRAFT VERSUS LYMPHOMA EFFECT FOR AGGRESSIVE T-CELL LYMPHOMAS IN ADULTS: A STUDY FROM THE SGFM-TG (SOCIÉTÉ FRANÇAISE DE GREFFE DE MOELLE ET DE THÉRAPIE CELLULAIRE)</td>
<td>S. Le Gouill et al (Nantes, FR)</td>
</tr>
<tr>
<td>18:20</td>
<td>032</td>
<td>HLA-IDENTICAL SIBLING ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT) FOR PATIENTS WITH PRIMARY CUTANEOUS T-CELL LYMPHOMA (CTCL)</td>
<td>R. Duarte et al (Barcelona, ES)</td>
</tr>
</tbody>
</table>

**17:30–18:30 PROFILING AND PROGNOSIS (room E)**

**Chair:** R. Dalla-Favera (New York, USA)
DIFFERENT SUBTYPES OF AGGRESSIVE B CELL LYMPHOMAS SHARE AN EPIGENETIC SIGNATURE ENRICHED FOR POLYCOMB TARGETS IN STEM CELLS
R. Siebert et al (Kiel, DE)

GENE EXPRESSION SIGNATURES PREDICT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA FOLLOWING RITUXIMAB AND CHOP-LIKE CHEMOTHERAPY
G. Lenz et al (Bethesda, USA)

GENE EXPRESSION PROFILING OF PERIPHERAL T-CELL LYMPHOMA INCLUDING GAMMA/DELTA T-CELL LYMPHOMA
K. Miyazaki et al (Tsu, JP)

ARRAY-CGH MAPPING OF AN OVERREPRESENTED 7Q REGION IN g/d HEPATOSPLENIC T-CELL LYMPHOMA
I. Wlodarska et al (Leuven, BE)

GENE EXPRESSION PROFILING REVEALS DISTINCT MOLECULAR SIGNATURES FOR NASAL NK/T-CELL LYMPHOMAS AND HEPATOSPLENIC T-CELL LYMPHOMAS
Y. Huang et al (Creteil, FR)

GENOME-WIDE PROFILING OF FOLLICULAR LYMPHOMA (FL) BY ARRAY COMPARATIVE GENOMIC HYBRIDIZATION (ACGH) REVEALS PROGNOSTICALLY SIGNIFICANT DNA COPY NUMBER IMBALANCES
K.J. Cheung et al (Vancouver, CA)

DIFFUSE LARGE B-CELL LYMPHOMA WITH RENAL INVOLVEMENT: OUTCOME AND RISK OF CENTRAL NERVOUS SYSTEM RELAPSE
D. Villa et al (Vancouver, CA)

LONG-TERM FOLLOW-UP OF THE C5R PROTOCOL OF HIGH-DOSE CHEMOTHERAPY AND RADIOTHERAPY IN 100 NEWLY DIAGNOSED PRIMARY CNS LYMPHOMAS: A PROSPECTIVE MULTICENTRIC PHASE II STUDY OF THE GELA
H. Ghesquieres et al (Lyon, FR)

CHLAMYDIA INFECTION AND LYMPHOMA: MULTIPLE DETECTION METHODS HIGHLIGHT AN ASSOCIATION BEYOND LYMPHOMAS OF THE OCULAR ADNEXA
M. Ponzoni et al (Milan, IT)

STAT6 ACTIVITY IS REGULATED BY SOCS-1 AND MODULATES BCL-XL EXPRESSION IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA
P. Möller et al (Ulm, DE)

THE ADDITION OF RITUXIMAB TO DOSE-ADJUSTED (DA)-EPOCH OBVIATES THE NEED FOR RADIATION IN THE TREATMENT OF PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBL); A PROSPECTIVE STUDY OF 58 PATIENTS
K. Dunleavy et al (Bethesda, USA)

RITUXIMAB DOES NOT IMPROVE SURVIVAL OF PATIENTS TREATED WITH M/VACOP-B PLUS RADIOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL); AN ITALIAN PHASE II STUDY OF INTERGRUPPO ITALIANO LINFOMI (IIL)
M. Martelli (Rome, IT)

PRIMARY MEDIASTINAL AND OTHER EXTRANODAL LYMPHOMA (Marquee Parco Ciani)
Chair: M. Gospodarowicz (Toronto, CA)

DIFFUSE LARGE B-CELL LYMPHOMA WITH RENAL INVOLVEMENT: OUTCOME AND RISK OF CENTRAL NERVOUS SYSTEM RELAPSE
D. Villa et al (Vancouver, CA)

LONG-TERM FOLLOW-UP OF THE C5R PROTOCOL OF HIGH-DOSE CHEMOTHERAPY AND RADIOTHERAPY IN 100 NEWLY DIAGNOSED PRIMARY CNS LYMPHOMAS: A PROSPECTIVE MULTICENTRIC PHASE II STUDY OF THE GELA
H. Ghesquieres et al (Lyon, FR)

CHLAMYDIA INFECTION AND LYMPHOMA: MULTIPLE DETECTION METHODS HIGHLIGHT AN ASSOCIATION BEYOND LYMPHOMAS OF THE OCULAR ADNEXA
M. Ponzoni et al (Milan, IT)

STAT6 ACTIVITY IS REGULATED BY SOCS-1 AND MODULATES BCL-XL EXPRESSION IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA
P. Möller et al (Ulm, DE)

THE ADDITION OF RITUXIMAB TO DOSE-ADJUSTED (DA)-EPOCH OBVIATES THE NEED FOR RADIATION IN THE TREATMENT OF PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBL); A PROSPECTIVE STUDY OF 58 PATIENTS
K. Dunleavy et al (Bethesda, USA)

RITUXIMAB DOES NOT IMPROVE SURVIVAL OF PATIENTS TREATED WITH M/VACOP-B PLUS RADIOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL); AN ITALIAN PHASE II STUDY OF INTERGRUPPO ITALIANO LINFOMI (IIL)
M. Martelli (Rome, IT)
Thursday, June 05, 2008

07:30–08:00
POSTER SET UP I (Marquee Parco Ciani)

08:00–18:30
POSTER SESSION I (Marquee Parco Ciani, authors present during lunch time)

EPIDEMIOLOGY
HODGKIN’S LYMPHOMA
PEDIATRIC LYMPHOMA
AGGRESSIVE LYMPHOMA
T-CELL LYMPHOMA
NEW TREATMENT MODALITIES

MEET THE PROFESSOR
NEW MONOClonAL ANTIBODIES FOR NON-HODGKIN’S LYMPHOMAS (room A)
J.P. Leonard et al (New York, USA)

PROGNOSTIC FACTORS IN CLL (room B I)
M.J. Hallek (Cologne, DE)

BURKITT LYMPHOMA VERSUS DIFFUSE LARGE B-CELL LYMPHOMA (room B II)
A. Rosenwald et al (Würzburg, DE)

NON-MALT MARGINAL ZONE LYMPHOMAS (room C)
C. Thieblemont (Paris, FR)

AMYLOIDOSIS: IS A CURE POSSIBLE? (room E)
G. Merlini et al (Pavia, IT)

UPDATE ON T-CELL LYMPHOMA (Marquee Parco Ciani)
J.M. Vose (Omaha, USA)

08:00–08:45
MEET THE PROFESSOR

(10:00–10:30)
SESSION 3 – BIOLOGY AND NOVEL RATIONAL THERAPEUTIC TARGETS IN
DLBCL (room A, Marquee Parco Ciani)
Co-chairs: M.J. Keating (Houston, USA) and M.A. Shipp (Boston, USA)

09:00 045 RESTORING APOPTOSIS TO LYMPHOMA BY TARGETING BCL-2
A. Letai (Boston, USA)

09:20 046 THERAPEUTIC TARGETING OF THE BCL6 ONCOGENE IN DIFFUSED LARGE B-
CELL LYMPHOMAS
A. Melnick (New York, USA)

09:40 047 MOLECULAR HETEROGENEITY AND RATIONAL THERAPEUTIC TARGETS IN
DLBCL
M.A. Shipp (Boston, USA)

10:00 048 Deregulation of the NFKB PATHWAY BY ONCOGENIC LESIONS IN ABC-
DLBCL
L. Pasqualucci et al (New York)

10:15 049 SUBSETS OF NHL POPULATIONS MEET CRITERIA FOR LYMPHOMA STEM CELLS
F. Young et al (Rochester, USA)

09:00–10:30
CLINICAL CASE DISCUSSION SESSIONS

(3 parallel sessions)
AGGRESSIVE NHL (room B I)
Chair: J.O. Armitage (Omaha, USA) – Presenter: M. Ghilimini (Bellinzona, CH)
Discussants: D. Linch (London, GB) and W.H. Wilson (Bethesda, USA)

INDOLENT NHL (room B II)
Chair: D.G. Maloney (Seattle, USA) – Presenter: S. Montoto (London, GB)
Discussants: P.W.M. Johnson (Southampton, GB) and J.P. Leonard (New York, USA)

HODGKIN’S LYMPHOMA (room C)
Chair: J.M. Connors (Vancouver, CA) – Presenter: L. Wannesson (Bellinzona, CH)
Discussants: A. Engert (Cologne, DE) and C. Moskowitz (New York, USA)

10:30–10:50
COFFEE BREAK (Marquee Parco Ciani)

10:50–12:20
SESSION 4 – DIFFUSE LARGE B-CELL LYMPHOMAS (Room A, B, Marquee Parco Ciani)
Co-chairs: B. Coiffier (Pierre Bénite, FR) and R.I. Fisher (Rochester, USA)

10:50 050 GENE EXPRESSION SUBTYPES OF DIFFUSE LARGE B CELL LYMPHOMA ARISE BY
DISTINCT GENETIC PATHWAYS
G. Lenz et al (Bethesda, USA)

11:05 051 P21, BCL-2, AND THE IPI, BUT NOT BCL-6, PREDICT CLINICAL OUTCOME IN
DLBCL TREATED WITH RITUXIMAB-CHOP: LONG-TERM FOLLOW UP FROM
E4494
J.N. Winter et al (Chicago, USA)

11:20 052 LIMITED-STAGE DLBCL PATIENTS WITH A NEGATIVE PET SCAN FOLLOWING
THREE CYCLES OF R-CHOP HAVE AN EXCELLENT OUTCOME FOLLOWING
ABBREVIATED IMMUNO-CHEMOTHERAPY ALONE
L.H. Sehn et al (Vancouver, CA)
11:35 053 IMPROVED OUTCOME OF ELDERLY PATIENTS WITH POOR-PROGNOSIS DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AFTER DOSE-DENSE RITUXIMAB®: RESULTS OF THE DENSE-R-CHOP-14 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP (DHSNL)
M. Pfreundschuh et al (Homburg/Saar, DE)

11:50 054 SEQUENTIAL RCHOP AND YTTRIUM-90 IBRITUMOMAB TIUXETAN (RIT) IS A HIGHLY EFFECTIVE REGIMEN FOR HIGH RISK ELDERLY PATIENTS WITHUNTREATED DLBCL
P.A. Hamlin et al (New York, USA)

12:05 054bis FIRST RESULT OF AN INTERNATIONAL STUDY TO ESTABLISH A NEW CLINICO-BIOLOGICAL PROGNOSTIC INDEX FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
G. Salles et al (Pierre Bénite, FR)

12:20–13:15 LUNCH TIME AND POSTER VIEWING (Marquee Parco Ciani)

13:15–14:00 002 HENRY RAPPAPORT MEMORIAL LECTURE (room A, B, Marquee Parco Ciani)
Chair: B. Nathwani (Los Angeles, USA)
THE ROLE OF THE MICROENVIRONMENT IN LYMPHOMA BIOLOGY
R. Gascoyne (Vancouver, CA)

14:00–15:30 SESSION 5 – FOLLICULAR LYMPHOMA / CLL (room A, B, Marquee Parco Ciani)
Co-chairs: K.R. Rai (New York, USA) and E. Zucca (Bellinzona, CH)

14:00 055 METHYLATION PROFILING IN 158 CASES OF PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL)
C. O'Riain et al (London, GB)

14:15 056 FOLLICULAR LYMPHOMA DERIVED B CELLS ARE SUFFICIENT TO CONVERT CD4+ T CELLS INTO CD4+CD25+FOXP3+ REGULATORY T CELLS VIA CELL-CELL CONTACT WITHOUT STIMULATION OF T CELL RECEPTOR
W. Ai et al (San Francisco, USA)

14:30 057 RESULTS OF A PHASE 3 TRIAL EVALUATING SAFETY AND EFFICACY OF SPECIFIC IMMUNOTHERAPY, RECOMBINANT IDIOTYPE (ID) CONJUGATED TO KLH (ID-KLH) WITH GM-CSF, COMPARED TO NON-SPECIFIC IMMUNOTHERAPY, KLH WITH GM-CSF, IN PATIENTS WITH FOLLICULAR NON-HODGKINS LYMPHOMA (FNHL)
R. Levy et al (Stanford, USA)

14:45 058 F2 PROGNOSTIC INDEX
M. Federico et al (Modena, IT)

15:00 059 STRIKING DIFFERENCES IN THE IG REPORTEIRO BETWEEN CLL AND MBL: IMPLICATIONS FOR THE PATHOGENESIS OF THE DISEASE
P. Ghia et al (Milan, IT)

15:15 060 A PROSPECTIVE MULTICENTER TRIAL ON NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION (NST) FOR POOR-RISK CHRONIC LYMPHOCTYIC LEUKEMIA (CLL): FINAL RESULTS OF THE GCLLSG CLL3X STUDY
P. Dreger et al (Heidelberg, DE)

15:30–15:50 COFFEE BREAK (Marquee Parco Ciani)

15:50–17:20 SESSION 6 – EXTRANODAL LYMPHOMA (room A, Marquee Parco Ciani)
Co-chairs: M. Gospodarowicz (Toronto, CA) and C. Thieblemont (Paris, FR)

15:50 061 THE NF-KB PATHWAY COMPONENT A20 (TNFAIP3) IS COMMONLY INACTIVATED BY DNA MUTATIONS AND DELETIONS IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (EMZL)
F. Bertoni et al (Bellinzona, CH)

16:05 062 LONG-TERM OUTCOME FOLLOWING RADIOTHERAPY IN LOCALIZED EXTRANODAL MALT LYMPHOMAS
J. Goda et al (Toronto, CA)

16:20 063 RITUXIMAB CHOP WITH CNS AND CONTRALATERAL TESTIS PROPHYLAXIS IMPROVES THE OUTCOME OF PRIMARY TESTICULAR LYMPHOMA (PTL): FINAL RESULTS OF IELSG10 STUDY
U. Vitolo et al (Bellinzona, CH)

16:35 064 MENINGEAL DISSEMINATION (MD) IN PRIMARY CNS LYMPHOMA (PCNSL)
A. Kerbel et al (Berlin, DE)

16:50 065 RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY (CHT) WITH HIGH-DOSE METHOTREXATE (MTX) ALONE OR ASSOCIATED WITH HIGH-DOSE CYTARABINE (ARAC) FOR PATIENTS (PTS) WITH PRIMARY CNS LYMPHOMA (PCNSL)
A.J. Ferreri et al (Milan, IT)
17:05 066 HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION AS FIRSTLINE TREATMENT OF PRIMARY CNS LYMPHOMA IN PATIENTS < 65 YEARS - UPDATED RESULTS FROM A PILOT AND PHASE II STUDY

G. Illerhaus et al (Freiburg, DE)

16:35 067 CD5 POSITIVE SPLENIC MARGINAL ZONE LYMPHOMA: CYTOLOGICAL, IMMUNOLOGICAL, CYTOGENETICAL AND MOLECULAR FEATURES OF A SERIES OF 35 CASES

L. Basergio et al (Pierre Bénite, FR)

16:05 068 PERNERAL T-CELL LYMPHOMAS WITH A FOLLICULAR GROWTH PATTERN: A PECULIAR LYMPHOMA SUBTYPE DERIVED FROM FOLLICULAR HELPER T CELLS (Tfh) WITH A POSSIBLE LINK TO ANGIOIMMUNOBLASTIC T-CELL LYMPHOMAS

Y. Huang et al (Creteil, FR)

16:20 069 INDUCTION OF A HODGKIN-LIKE PHENOTYPE IN AGGRESSIVE B-CELL LYMPHOMA CELLS BY EPIGENETIC REPROGRAMMING

H. Stein et al (Berlin, DE)

17:05 070 COMPOSITE FOLLICULAR (FL) AND DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A GENE EXPRESSION PROFILING (GEP) STUDY

P. Farinha et al (Vancouver, CA)

16:05 068 PERIPHERAL T-CELL LYMPHOMAS WITH A FOLLICULAR GROWTH PATTERN: A PECULIAR LYMPHOMA SUBTYPE DERIVED FROM FOLLICULAR HELPER T CELLS (Tfh) WITH A POSSIBLE LINK TO ANGIOIMMUNOBLASTIC T-CELL LYMPHOMAS

Y. Huang et al (Creteil, FR)

15:50–18:20 SESSION 7 – PATHOLOGY AND CLINICAL / PATHOLOGICAL CORRELATIONS (room B)

Co-chairs: E. Campo (Barcelona, ES) and N.L. Harris (Boston, USA)

15:50 067 CD5 POSITIVE SPLENIC MARGINAL ZONE LYMPHOMA: CYTOLOGICAL, IMMUNOLOGICAL, CYTOGENETICAL AND MOLECULAR FEATURES OF A SERIES OF 35 CASES

L. Basergio et al (Pierre Bénite, FR)

16:05 071 CUT-OFF VALUE DETERMINATION FOR PROGNOSTIC MARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

S. Dirmhofer et al (Basel, CH)

17:35 072 COMPOSITE FOLLICULAR (FL) AND DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A GENE EXPRESSION PROFILING (GEP) STUDY

P. Farinha et al (Vancouver, CA)

17:05 073 NEW METHODS FOR FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE (FFPET) SAMPLE MICROARRAY ANALYSIS PERMIT ACCURATE PREDICTION OF GCB AND ABC SUBTYPES OF DLBCL

M. Williams et al (Pleasanton, USA)

15:50–18:20 SESSION 8 – PEDIATRIC LYMPHOMA (room C)

Chair: A. Reiter (Giessen, DE)

15:50 077 RADIATION THERAPY IN PEDIATRIC HODGKIN DISEASE – WHO NEEDS IT?

J.B. Nachman (Chicago, USA)

15:50 078 THE ROLE OF FDG-PET FOR GUIDANCE OF TREATMENT OF CHILDHOOD AND ADOLESCENCE HODGKIN LYMPHOMA

D. Körholz et al (Halle, DE)

15:50–18:20 SESSION 8 – PEDIATRIC LYMPHOMA (room C)

Chair: A. Reiter (Giessen, DE)

15:50 077 RADIATION THERAPY IN PEDIATRIC HODGKIN DISEASE – WHO NEEDS IT?

J.B. Nachman (Chicago, USA)

15:50 078 THE ROLE OF FDG-PET FOR GUIDANCE OF TREATMENT OF CHILDHOOD AND ADOLESCENCE HODGKIN LYMPHOMA

D. Körholz et al (Halle, DE)

15:50 079 A MULTI-CENTRE STUDY OF THE TREATMENT AND CHARACTERISATION OF BURKITT LYMPHOMA IN 4 AFRICAN COUNTRIES

T. Ngoma et al (Dar es-Salaam, Tanzania)

15:50–18:20 SESSION 8 – PEDIATRIC LYMPHOMA (room C)

Chair: A. Reiter (Giessen, DE)

15:50 077 RADIATION THERAPY IN PEDIATRIC HODGKIN DISEASE – WHO NEEDS IT?

J.B. Nachman (Chicago, USA)

15:50 078 THE ROLE OF FDG-PET FOR GUIDANCE OF TREATMENT OF CHILDHOOD AND ADOLESCENCE HODGKIN LYMPHOMA

D. Körholz et al (Halle, DE)

15:50 079 A MULTI-CENTRE STUDY OF THE TREATMENT AND CHARACTERISATION OF BURKITT LYMPHOMA IN 4 AFRICAN COUNTRIES

T. Ngoma et al (Dar es-Salaam, Tanzania)

15:50–18:20 SESSION 8 – PEDIATRIC LYMPHOMA (room C)

Chair: A. Reiter (Giessen, DE)

15:50 077 RADIATION THERAPY IN PEDIATRIC HODGKIN DISEASE – WHO NEEDS IT?

J.B. Nachman (Chicago, USA)

15:50 078 THE ROLE OF FDG-PET FOR GUIDANCE OF TREATMENT OF CHILDHOOD AND ADOLESCENCE HODGKIN LYMPHOMA

D. Körholz et al (Halle, DE)

15:50 079 A MULTI-CENTRE STUDY OF THE TREATMENT AND CHARACTERISATION OF BURKITT LYMPHOMA IN 4 AFRICAN COUNTRIES

T. Ngoma et al (Dar es-Salaam, Tanzania)

15:50–18:20 SESSION 8 – PEDIATRIC LYMPHOMA (room C)

Chair: A. Reiter (Giessen, DE)

15:50 077 RADIATION THERAPY IN PEDIATRIC HODGKIN DISEASE – WHO NEEDS IT?

J.B. Nachman (Chicago, USA)

15:50 078 THE ROLE OF FDG-PET FOR GUIDANCE OF TREATMENT OF CHILDHOOD AND ADOLESCENCE HODGKIN LYMPHOMA

D. Körholz et al (Halle, DE)

15:50 079 A MULTI-CENTRE STUDY OF THE TREATMENT AND CHARACTERISATION OF BURKITT LYMPHOMA IN 4 AFRICAN COUNTRIES

T. Ngoma et al (Dar es-Salaam, Tanzania)

15:50–18:20 SESSION 8 – PEDIATRIC LYMPHOMA (room C)

Chair: A. Reiter (Giessen, DE)

15:50 077 RADIATION THERAPY IN PEDIATRIC HODGKIN DISEASE – WHO NEEDS IT?

J.B. Nachman (Chicago, USA)

15:50 078 THE ROLE OF FDG-PET FOR GUIDANCE OF TREATMENT OF CHILDHOOD AND ADOLESCENCE HODGKIN LYMPHOMA

D. Körholz et al (Halle, DE)

15:50 079 A MULTI-CENTRE STUDY OF THE TREATMENT AND CHARACTERISATION OF BURKITT LYMPHOMA IN 4 AFRICAN COUNTRIES

T. Ngoma et al (Dar es-Salaam, Tanzania)

15:50–18:20 SESSION 8 – PEDIATRIC LYMPHOMA (room C)

Chair: A. Reiter (Giessen, DE)

15:50 077 RADIATION THERAPY IN PEDIATRIC HODGKIN DISEASE – WHO NEEDS IT?

J.B. Nachman (Chicago, USA)

15:50 078 THE ROLE OF FDG-PET FOR GUIDANCE OF TREATMENT OF CHILDHOOD AND ADOLESCENCE HODGKIN LYMPHOMA

D. Körholz et al (Halle, DE)

15:50 079 A MULTI-CENTRE STUDY OF THE TREATMENT AND CHARACTERISATION OF BURKITT LYMPHOMA IN 4 AFRICAN COUNTRIES

T. Ngoma et al (Dar es-Salaam, Tanzania)
PRELIMINARY RESULTS OF A PHASE II STUDY OF CHEMOIMMUNOTHERAPY (RITUXIMAB + FAB CHEMOTHERAPY) IN CHILDREN AND ADOLESCENTS WITH INTERMEDIATE RISK B-CELL NHL: A CHILDREN'S ONCOLOGY GROUP REPORT

WHERE IS THE PLACE FOR RITUXIMAB IN THE TREATMENT OF B-CELL NON-HODGKIN LYMPHOMA (B-NHL) OF CHILDREN AND ADOLESCENTS?

“FOCUS ON…” SESSIONS (3 parallel sessions):

SNP ARRAY GENOTYPING IN 182 DIAGNOSTIC FOLLICULAR LYMPHOMA CASES IDENTIFIES SITES OF AUPD ASSOCIATED WITH OVERALL SURVIVAL AND RISK OF TRANSFORMATION

CHANGES IN FOLLICULAR LYMPHOMA ARE RELATED TO TIME TO TRANSFORMATION TO DIFFUSE LARGE B-CELL LYMPHOMA

TRANSFORMED DIFFUSE LARGE B-CELL LYMPHOMAS DIFFER FROM FOLLICULAR LYMPHOMAS IN BOTH GENE AND PROTEIN EXPRESSION

IMPROVED PROGNOSIS AFTER HISTOLOGIC TRANSFORMATION (HT) OF FOLLICULAR LYMPHOMA (FL); THE STANFORD EXPERIENCE 1960-2003

A RETROSPECTIVE COHORT OF LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA: A LONG-TERM OUTCOME AND THE RISK OF TRANSFORMATION INTO DIFFUSE LARGE-B CELL LYMPHOMA

FREQUENCY OF TRANSFORMATION TO DIFFUSE LARGE B-CELL LYMPHOMA IN NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA: THE BCCA EXPERIENCE

CORRELATION BETWEEN EBV RNA EXPRESSION AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) EXPRESSION IN DIFFERENT SUBTYPES OF PERIPHERAL T-CELL LYMPHOMAS (PTCL) AND PROGNOSTIC IMPLICATIONS

A NEW PROGNOSTIC MODEL FOR PERIPHERAL T/NK-CELL LYMPHOMAS (PTCLS) FROM PROSPECTIVE MULTICENTER CLINICAL TRIALS

T-CELL LYMPHOMAS IN STUDIES OF THE GERMAN HIGH-GRADE NHL STUDY GROUP (DSHNHL)

MATURER T-CELL LYMPHOMA PATIENTS SHOW HIGH RELAPSE RATES AFTER HIGH DOSE THERAPY FOLLOWED BY AUTOLOGOUS TRANSPLANTATION

PHASE II STUDY OF DENILEUKIN DIFTITOX WITH CHOP IN PTCL

INCREASED RISK TO DEVELOP ANAPLASTIC LARGE CELL LYMPHOMA IN WOMEN WITH BREAST IMPLANTS

GA101, A NOVEL THERAPEUTIC TYPE II CD20 ANTIBODY WITH OUTSTANDING ANTI-TUMOR EFFICACY IN NON-HODGKIN LYMPHOMA XENOGRAFT MODELS AND SUPERIOR B CELL DEPLETION

SGN-40 SHOWS EVIDENCE OF ACTIVITY IN PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA: FINAL RESULTS OF A PHASE I DOSE-ESCALATION STUDY

IDENTIFICATION OF CD20 MUTATION ASSOCIATED WITH MODIFICATION OF CD20 EXPRESSION AND POOR PROGNOSIS AFTER RITUXIMAB IN NON-
HODGKIN’S LYMPHOMA
Y. Terui et al (Tokyo, JP)

18:00 101
A PHASE I STUDY EVALUATING THE SAFETY, PK & EFFICACY OF ABT-263 IN
SUBJECTS WITH REFRRACTORY OR RELAPSED LYMPHOID MALIGNANCIES
O.A. O’Connor et al (New York, USA)

18:10 102
TAMATINIB FOSDIUM (TAMF), AN ORAL SYK INHIBITOR, HAS SIGNIFICANT
CLINICAL ACTIVITY IN B-CELL NON-HODGKIN’S LYMPHOMA (NHL)
J. Friedberg et al (Rochester, USA)

18:20 103
INTERNATIONAL TRIAL CONFIRMS ROMIPESIN EFFICACY IN REFRACTORY
CTCL PATIENTS
A. Prentice et al (London, GB)
## Friday, June 06, 2008

### 07:30–08:00

**POSTER SET UP II** (Marquee Parco Ciani)

**POSTER SESSION II** (Marquee Parco Ciani, authors present during lunch time)

<table>
<thead>
<tr>
<th>Pathology</th>
<th>266–272</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphoma Biology</td>
<td>273–291</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>292–295</td>
</tr>
<tr>
<td>Mantle Cell Lymphoma</td>
<td>296–308</td>
</tr>
<tr>
<td>Indolent Lymphoma</td>
<td>309–345</td>
</tr>
<tr>
<td>Extranodal Lymphoma</td>
<td>346–368</td>
</tr>
<tr>
<td>CLL</td>
<td>369–385</td>
</tr>
</tbody>
</table>

### 08:00–18:30

#### 08:00–08:45

**MEET THE PROFESSOR**

<table>
<thead>
<tr>
<th>VI</th>
<th>Radiotherapy in Non-Hodgkin Lymphomas (room A)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VII</td>
<td>Prognostic Factors in CLL (room B I)</td>
</tr>
<tr>
<td>XV</td>
<td>Extranodal Lymphoma: A Reappraisal (room B II)</td>
</tr>
<tr>
<td>XI</td>
<td>Amyloidosis: Is a Cure Possible? (room C)</td>
</tr>
<tr>
<td>V</td>
<td>Treatment of Lymphocyte Predominant Hodgkin Lymphoma (room E)</td>
</tr>
<tr>
<td>IV</td>
<td>Current Treatment Standards and Future Strategies in Mantle Cell Lymphomas (Marquee Parco Ciani)</td>
</tr>
</tbody>
</table>

### 09:00–10:15

**SESSION 9 – MICRO-RNA IN LYMPHOID MALIGNANCIES** (room A, Marquee Parco Ciani)

**Chair:** C.M. Croce (Columbus, USA)

<table>
<thead>
<tr>
<th>09:00</th>
<th>104 RNA Interference-Based Genetic Screening Meets Cancer Genome Resequencing</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:20</td>
<td>105 Role of Micro-RNAs in Normal B Cell Development and Lymphoma-Genesis</td>
</tr>
<tr>
<td>09:40</td>
<td>106 MicroRNA Control in Lymphocyte Physiology and Pathology</td>
</tr>
<tr>
<td>10:00</td>
<td>107 Concomitant Gene Expression Profiling and Micro-RNA Profiling Reveal a Role for Micro-RNAs in B Cell Development and Lymphomas at Every Stage</td>
</tr>
</tbody>
</table>

### 09:00–10:30

**CLINICAL CASE DISCUSSION SESSIONS** (3 parallel sessions)

<table>
<thead>
<tr>
<th>T-CELL (room B I)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair:</strong> P.L. Zinzani (Bologna, IT) – Presenter: A.Z.S. Rohatiner (London, GB)</td>
</tr>
<tr>
<td>Discussants: J.F. Seymour (Melbourne, AU) and J.M. Vose (Omaha, USA)</td>
</tr>
<tr>
<td><strong>EXTRANODAL LYMPHOMA (room B II)</strong>*</td>
</tr>
<tr>
<td><strong>Chair:</strong> T.A. Lister (London, GB) – Presenter: E. Zucca (Bellinzona, CH)</td>
</tr>
<tr>
<td>Discussants: M. Gospodarowicz (Vancouver, CA) and C. Thieblemont (Paris, FR)</td>
</tr>
<tr>
<td><strong>CLL (room C)</strong>*</td>
</tr>
<tr>
<td><strong>Chair:</strong> E. Montserrat (Barcelona, ES) – Presenter: J. Gribben (London, GB)</td>
</tr>
<tr>
<td>Discussants: M.J. Hallek (Cologne, DE) and M.J. Keating (Houston, USA)</td>
</tr>
</tbody>
</table>

### 10:30–10:50

**COFFEE BREAK** (Marquee Parco Ciani)

### 10:50–12:10

**SESSION 10 – REVIEW LECTURES** (room A, B, Marquee Parco Ciani)

<table>
<thead>
<tr>
<th>10:50</th>
<th>108 Grey Zone Lymphomas</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:10</td>
<td>109 CNS Involvement in Lymphomas</td>
</tr>
<tr>
<td>11:30</td>
<td>110 Current Treatment Approaches in Multiple Myeloma</td>
</tr>
<tr>
<td>11:50</td>
<td>111 Chronic Lymphocytic Leukaemia: Progress and Challenges</td>
</tr>
</tbody>
</table>

### 12:10–13:15

**LUNCH TIME AND POSTER VIEWING** (Marquee Parco Ciani)

### 13:15–14:00

**JOHN ULMANN MEMORIAL LECTURE*** (room A, B, Marquee Parco Ciani)

**Chair:** S.J. Horning (Stanford, USA)

<table>
<thead>
<tr>
<th>003</th>
<th>Are We Changing the Natural History of Follicular Lymphoma?</th>
</tr>
</thead>
</table>

*Supported by ASCO*
14:00–15:00

SESSION 11 – SPECIAL TOPIC: CLASSIFYING LYMPHOMA (room A, B, Marquee Parco Ciani)

Co-chairs: J.O. Armitage (Omaha, USA) and E. Campo (Barcelona, ES)

14:00 112 THE WORLD HEALTH ORGANIZATION (WHO) CLASSIFICATION OF LYMPHOID NEOPLASMS: WHAT’S NEW?
N.L. Harris et al (Boston, USA)

14:30 113 PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED: A CLINICOPATHOLOGIC STUDY OF 340 CASES FROM THE INTERNATIONAL PERIPHERAL T-CELL LYMPHOMA PROJECT
D.D. Weisenburger et al (Omaha, USA)

14:45 114 ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: A REPORT FROM THE INTERNATIONAL PERIPHERAL T-CELL LYMPHOMA PROJECT
T. Rudiger et al (Karlsruhe, DE)

15:00–15:20

COFFEE BREAK (Marquee Parco Ciani)

15:20–16:35

SESSION 12 – HODGKIN’S LYMPHOMA (room A, B, Marquee Parco Ciani)

Co-chairs: J.M. Connors (Vancouver, CA) and V. Diehl (Cologne, DE)

15:20 115 NEW INSIGHTS IN CLASSICAL HODGKIN LYMPHOMA (CHL) PATHOGENESIS AS REVEALED BY GENE EXPRESSION PROFILING OF MICRORASSECTED HODGKIN/REED-STERNBERG (HRS) CELLS
E. Tiacci et al (Essen, DE)

15:35 116 PET-BASED EVALUATION OF RESIDUAL TISSUE IN ADVANCED-STAGE HODGKIN LYMPHOMA: GHSG INTERIM ANALYSIS OF THE HD15 TRIAL
A. Engert et al (Cologne, DE)

15:50 117 INVOLVED-NODAL RADIOTHERAPY: CAN WE SAFELY REDUCE THE FIELD SIZE FOR LIMITED STAGE HODGKIN LYMPHOMA TREATED WITH COMBINED MODALITY THERAPY?
B.A. Campbell et al (Vancouver, CA)

16:05 118 DEFINING A POPULATION OF HODGKIN LYMPHOMA PATIENTS FOR NOVEL THERAPEUTICS: AN INTERNATIONAL EFFORT
S.J. Horning et al (Stanford, USA)

16:20 119 SECONDARY MALIGNANCIES IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA TREATED WITH AN AUTOLOGOUS STEM CELL TRANSPLANTATION. AN ANALYSIS OF THE LYMPHOMA WP OF THE EBMT
M. Sieniawski et al (Newcastle upon Tyne, GB)

16:35–17:30

CONTROVERSY II: HAS PET CHANGED THE APPROACH TO LYMPHOMA PATIENTS? (room A, B, Marquee Parco Ciani)
Chair: T.A. Lister (London, GB)

120-121 PROS: S. Stroobants (Leuven, BE) vs COS: B.D. Cheson (Washington, USA)

17:30–18:30

FAREWELL APERITIF (Marquee Parco Ciani)
with the performance of ‘Le Donne Virtuose’ (string quartet)
08:00–08:50

**FOCUS ON...** SESSIONS (2 parallel sessions)

**PET** (room A)

*Chair: P.W.M. Johnson (Southampton, GB)*

08:00  122 FLUORINE-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN MATURE T-CELL AND NATURAL KILLER CELL MALIGNANCIES

W.Y. Au et al (Hong Kong, HK)

08:10  123 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY (18F-FDG-PET) IN PATIENTS WITH LYMPHOMA OF THE GASTROINTESTINAL TRACT ACCORDING TO THE WHO-CLASSIFICATION: THE VIENNA UNIVERSITY EXPERIENCE

M. Hoffmann et al (Vienna, AT)

08:20  124 FDG-PET DURING FOLLOW-UP IN PATIENTS WITH HODGKIN LYMPHOMA AFTER FIRST LINE THERAPY

H. Mocikova et al (Prague, CZ)

08:30  125 MULTIVARIATE ANALYSIS OF PATIENTS WITH HODGKIN LYMPHOMA TRANSPLANTED WITH PET-AVID DISEASE

C. Moskowitz et al (New York, USA)

08:40  126 FDG-PET SCAN GUIDED CONSOLIDATIVE RADIATION THERAPY MAY IMPROVE OUTCOME IN PATIENTS WITH ADVANCED-STAGE AGGRESSIVE NHL WITH RESIDUAL ABNORMALITIES ON CT SCAN FOLLOWING CHEMOTHERAPY

L.H. Sehn et al (Vancouver, CA)

**Lymphoma Biology** (room B)

08:00  127 DETECTION OF MYC MUTATIONS IN MOLECULARLY CLASSIFIED AGGRESSIVE LYMPHOMAS

Ch. Pott et al (Kiel, DE)

08:10  128 CMYC TRANSLOCATIONS MAY BE FOUND IN FOLLICULAR LYMPHOMA IN THE ABSENCE OF TRANSFORMATION OR PROGRESSIVE DISEASE

K. Turner et al (Leeds, GB)

08:20  129 THE PROGNOSTIC VALUE OF THE TUMOR/MICROENVIRONMENT SIGNATURE COMPARED TO EARLY PET SCAN IN ADVANCED-STAGE, ABVD-TREATED HODGKIN LYMPHOMA PATIENTS

A. Gallamini et al (Cuneo, IT)

08:30  130 HIGH NUMBERS OF TUMOR INFILTRATING PD-1-POSITIVE REGULATORY LYMPHOCYTES ARE ASSOCIATED WITH IMPROVED SURVIVAL IN FOLLICULAR LYMPHOMA

A. Lopez-Guillermo et al (Barcelona, ES)

08:40  131 THE IMPACT OF TUMOUR MICROENVIRONMENT IN DIAGNOSTIC FOLLICULAR LYMPHOMA SAMPLES USING TISSUE MICROARRAYS

A.M. Lee et al (London, GB)

**SESSION 13 - NEW DRUGS** (room A)

Co-chairs: B.D. Cheson (Washington, USA) and O.A. O'Connor (New York, USA)

*organized on an unrestricted grant from Novartis*

09:00  132 NEW DRUGS, MAINLY IN MULTIPLE MYELOMA

J.F. San-Miguel (Salamanca, ES)

09:20  133 NEW DRUGS FOR B-CELL IN NON-HODGKIN’S LYMPHOMAS (NHL)

B.D. Cheson (Washington, USA)

09:40  134 NEW DRUGS FOR THE TREATMENT OF T-CELL LYMPHOMA

O.A. O’Connor (New York, USA)

10:00  135 ALL B LYMPHOMA SUBTYPE DO NOT SHARE SIMILAR OUTCOME AFTER FRONT-LINE R-CHOP PLUS BORTEZOMIB TREATMENT: A RANDOMIZED PHASE 2 TRIAL FROM THE GROUPE D’ETUDE DES LYMPHOMES DE L’ADULTE (GELA)

N. Mounier et al (Paris, FR)

10:15  136 ORAL PANOBINOSTAT (LBH589), A NOVEL DEACETYLASE INHIBITOR (DACI), DEMONSTRATES CLINICAL ACTIVITY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL)

A. Spencer et al (Melbourne, AU)

10:30  137 ISOYPE-SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITOR MGCD0103 DEMONSTRATES CLINICAL ACTIVITY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (HL)

A. Younes et al (Houston, USA)
10:45 138 PRALATREXATE (PDX) PRODUCES A HIGH AND DURABLE COMPLETE RESPONSE RATE IN PATIENTS WITH CHEMOTHERAPY RESISTANT T-CELL LYMPHOMAS
O.A. O'Connor et al (New York, USA)

09:00–10:50 SESSION 14 – BIOLOGICAL TREATMENTS (room B)
Co-chairs: A. Lanzavecchia (Bellinzona, CH) and J.M. Vose (Omaha, USA)

09:00 139 NEW IMMUNOLOGIC TREATMENTS FOR LYMPHOMA
R. Levy et al (Stanford, USA)

09:20 140 RITUXIMAB AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY: A REPORT OF 35 CASES
K.R. Carson et al (Chicago, USA)

09:35 141 OBJECTIVE RESPONSES IN A PHASE I DOSE-ESCALATION STUDY OF SGN-35, A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) TARGETING CD30, IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
A. Younes et al (Houston, USA)

09:50 142 VACCINATION OF INDOLENT NON-HODGKIN LYMPHOMA PATIENTS WITH DENDRITIC CELLS LOADED WITH APOPTOTIC TUMOR CELLS INDUCES THE ACTIVATION OF NK CELLS AND THE DECREASE OF REGULATORY T CELLS IN PERIPHERAL BLOOD AND AT TUMOR SITE IN RESPONDING PATIENTS
M. Di Nicola et al (Milan, IT)

10:05 143 A PHASE II TRIAL OF EXTENDED INDUCTION GALIXIMAB ([G] ANTI-CD80 MONOCLONAL ANTIBODY) PLUS RITUXIMAB® IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL): INITIAL REPORT OF CALGB 50402
M. S. Czuczman et al (Buffalo, USA)

10:20 144 ACTIVITY OF VELTUCUMAB, A SECOND-GENERATION HUMANIZED ANTI-CD20 MAB, IN LABORATORY AND CLINICAL STUDIES
D.M. Goldenberg et al (Belleville, USA)

10:35 145 LUMILIXIMAB IN COMBINATION WITH FCR FOR THE TREATMENT OF RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RESULTS FROM A PHASE I/II MULTICENTER STUDY
J. Byrd et al (Columbus, USA)

11:00 CLOSING REMARKS (room A, B)
S.J. Horning (Stanford, USA)
Educational Book

List of Meet the Professor articles:

I  AUTO-IMMUNE DISORDERS AND LYMPHOMA (F. Caligaris-Cappio, Milan, IT)
II  NEW RESPONSE CRITERIA FOR LYMPHOMAS IN CLINICAL TRIALS (B.D. Cheson, Washington, USA)
III  MICRORNAS AND LYMPHOMAS (C.M. Croce, Columbus, USA)
IV  CURRENT TREATMENT STANDARDS AND FUTURE STRATEGIES IN MANTLE CELL LYMPHOMA (M. Dreyling et al, Munich, DE)
V  TREATMENT OF LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA (A. Engert, Cologne, DE)
VI  RADIOTHERAPY IN NON-HODGKIN LYMPHOMAS (M. Gospodarowicz, Toronto, CA)
VII  PROGNOSTIC FACTORS IN CLL (M.J. Hallek, Cologne, DE)
VIII  MAINTENANCE TREATMENT IN MULTIPLE MYELOMA (J.-L. Harousseau, Nantes, FR)
IX  NEW TARGETS FOR LYMPHOMA TREATMENT (P.W.M. Johnson, Southampton, GB)
X  NEW MONOCLONAL ANTIBODIES FOR NON-HODGKIN’S LYMPHOMA (J.P. Leonard et al, New York, USA)
XI  AMYLOIDOSIS: IS A CURE POSSIBLE? (G. Merlini et al, Pavia, IT)
XII  BURKITT LYMPHOMA VERSUS DIFFUSE LARGE B-CELL LYMPHOMA (A. Rosenwald et al, Würzburg, DE)
XIII  NON-MALT MARGINAL ZONE LYMPHOMAS (C. Thieblemont, Paris, FR)
XIV  UPDATE ON T-CELL LYMPHOMA (J.M. Vose, Omaha, USA)
XV  EXTRANODAL LYMPHOMA: A REAPPRAISAL (E. Zucch, Bellinzona, CH)

Note. The 15 articles published in the 10-ICML EDUCATIONAL BOOK represent the presentations made at the ‘Meet the Professor’ sessions during the 10th International Conference on Malignant Lymphoma (10-ICML) held in Lugano, Switzerland on 04-07 June 2008.

All manuscripts submitted have been subjected to peer review, and authors have been requested to disclose any relationships with companies whose products or services are discussed in their manuscript.

Disclosed information is indicated as a footnote in each article.

*Professor Cavalli and Prof Ghielmini, as guest editors, have reported no financial relationships with companies whose products are mentioned in this supplement.
Schedules and Abstracts of Satellite Symposia
Tuesday, June 03, 2008, 13:00 – 15:00 (room A)

**CELGENE**

HODGKIN’S LYMPHOMA: ADVANCING BEYOND STANDARD MANAGEMENT
Chair: B.D. Cheson (Washington, USA)

A satellite symposium provided by The Center for Biomedical Continuing Education (CBCE) and supported by an educational grant from Celgene Corporation

12:30 - Registration and Reception

THE STANDARD APPROACH TO THE TREATMENT OF HODGKIN’S LYMPHOMA
B.D. Cheson (Washington, USA)

IMPROVEMENT OF CHEMOTHERAPY REGIMENS BEYOND ABVD
V. Diehl (Cologne, DE)

NOVEL TREATMENTS FOR HODGKIN’S LYMPHOMA
A. Younes (Houston, USA)

RISK-DIRECTED THERAPY (PET)
J. Radford (Manchester, UK)

Tuesday, June 03, 2008, 16:00 – 18:00 (room A)

**CEPHALON ONCOLOGY**

THE EVOLVING ROLE OF MULTIFUNCTIONAL AGENTS IN LYMPHOID MALIGNANCIES
Chair: B.D. Cheson (Washington, USA)

FACTORS LEADING TO RITUXIMAB RESISTANCE AND HOW TO OVERCOME THEM
D.G. Maloney (Seattle, USA)

NEWER STRATEGIES FOR OVERCOMING REFRACTORY OR RESISTANT NHL
B.D. Cheson (Washington, USA)

GERMAN EXPERIENCE WITH BENDAMUSTINE IN B-CELL LYMPHOMA
M. Rummel (Giessen, DE)

THE US CLINICAL EXPERIENCE WITH BENDAMUSTINE
J.W. Friedberg (Rochester, USA)

BIOLOGY AND NEW DIAGNOSTIC TOOLS IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
K.R. Rai (New York, USA)

ADVANCES IN CHEMOTHERAPY: BENDAMUSTINE FOR CHRONIC LYMPHOCYTIC LEUKEMIA
M. J. Hallek (Cologne, DE)
Tuesday, June 03, 2008, 16:00 – 18:00 (room B I)

AMGEN
ADVANCING THE OPTIONS FOR TREATMENT AND SUPPORT OF PATIENTS WITH HAEMATOLOGICAL DISORDERS
Chair: J.-L. Harousseau (Nantes, FR)
TREATMENT STRATEGIES FOR DIFFUSE LARGE B-CELL LYMPHOMA: THE GELA EXPERIENCE
B. Coiffier (Pierre Bénite, FR)
SUPPORTING THE WAY TOWARDS A CURE IN MULTIPLE MYELOMA
J.-L. Harousseau (Nantes, FR)
INNOVATIVE APPROACHES IN THE TREATMENT AND SUPPORT OF ACUTE MYELOID LEUKEMIA
R.F. Schlenk (Ulm, DE)
A BREAKTHROUGH IN THE TREATMENT OF ITP
M. Rummel (Giessen, DE)

Tuesday, June 03, 2008, 16:00 – 18:00 (room B II)

GLAXOSMITHKLINE
NEW PARADIGMS IN THE ANTI-CD20 TREATMENT OF LYMPHOID MALIGNANCIES
Chair: M.J. Keating (Houston, USA)
THE BIOLOGY OF B-CELL CD20 ANTIGEN AND ITS POTENTIAL AS A THERAPEUTIC TARGET
M. Czuczman (Buffalo, USA)
FOLLICULAR LYMPHOMA: OVERCOMING RITUXIMAB RESISTANCE
B. Coiffier (Pierre Bénite, FR)
THE NEXT GENERATION OF ANTIBODY THERAPIES FOR NHL
J.P. Leonard (New York, USA)
THERAPEUTIC IMPLICATIONS OF THE BIOLOGICAL PROFILE OF CLL
S. Stilgenbauer (Ulm, DE)
RISK-STRATIFIED APPROACH TO TREATMENT FOR PATIENTS WITH CLL
M.J. Keating (Houston, USA)
F. HOFFMANN-LA ROCHE LTD
GIVING YOUR PATIENTS THE BEST CHANCE OF CURE
Chair: M. Ghielmini (Bellinzona, CH)

MABTHERA-BASED THERAPY FOR DLBCL: INCREASING THE PATIENT’S CHANCE OF CURE
D. Linch (London, GB)

CHARTING 10 YEARS OF PROGRESS: ARE WE CLOSER TO CURE IN FL?
M. Ghielmini (Bellinzona, CH)

INDUCTION AND MAINTENANCE THERAPY FOR FL: MY CLINICAL PRACTICE
J.M. Connors (Vancouver, CA)

TRANSFORMING THE OUTLOOK FOR CLL PATIENTS
J. Gribben (London, GB)

LOOKING TO THE FUTURE OF LYMPHOMA THERAPY
J. Seymour (Melbourne, AU)

Wednesday, June 04, 2008 19:00-21:00 (room A)

BIOGEN IDEC ONCOLOGY
CHANGING PARADIGMS FOR THE TREATMENT OF LYMPHOID MALIGNANCIES
Co-chairs: A. Hagenbeek (Amsterdam, NL) and K.R. Rai (New York, USA)

PART I: CHOOSING THE RIGHT TREATMENT OPTION IN FOLLICULAR LYMPHOMA: THE ROLE OF NOVEL AGENTS IN THE RITUXIMAB ERA

CURRENT STANDARD OF CARE FOR INDOLENT FOLLICULAR LYMPHOMAS: IS THERE ANY BENEFIT TO WATCH AND WAIT?
R. Marcus (London, GB)

DOES IMMEDIATE TREATMENT UPON DIAGNOSIS AFFECT OUTCOME?
C. Thieblemont (Paris, FR)

NEW AGENTS ON THE HORIZON FOR THE TREATMENT OF LYMPHOID MALIGNANCIES
G. Morgan (London, GB)

BIOLOGICS AND ANTIBODY THERAPIES IN THE SETTINGS OF RELAPSED/REFRACTORY OR FIRST-LINE FOLLICULAR LYMPHOMA
M. Czuczman (Buffalo, USA)

INTERACTIVE DISCUSSION SESSION

PART II: CONTROVERSIES IN THE MANAGEMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

CASE PRESENTATIONS
K.R. Rai (New York, USA)

Case 1: Indolent CLL

Case 2: Aggressive form of CLL

CLL: WHAT IS THE BEST COURSE OF ACTION?
Moderator: K.R. Rai (New York, USA)

CHEMOTHERAPY, IMMUNOCHEMOTHERAPY, OR WATCH AND WAIT FOR CLL: WHO BENEFITS?
S. O’Brien (Houston, USA)

THE RELEVANCE OF NOVEL BIOLOGICS OR DENDRITIC CELL VACCINES FOR CLL
A. Nathwani (London, GB)
Wednesday, June 04, 2008 19:00-21:00 (room B I)

MUNDIPHARMA
WHICH PROBLEMS REMAIN TO BE SOLVED IN NON-HODGKIN LYMPHOMAS?

PART I:
Chair: M. Dreyling (Munich, DE)
IS THERE STILL A ROLE FOR TRANSPLANTATION IN 1ST RELAPSE OF INDOLENT LYMPHOMAS?
A PRO-CONTRA DISCUSSION
Yes: J. Gribben (London, GB).
No: M. Rummel (Giessen, DE)

PART II:
Chair: C. Gisselbrecht (Paris, FR)
FLOW-CYTOMETRY IN HIGH-RISK PATIENTS – A NEW HIGHLY SENSITIVE STANDARD
D. Caballero (Salamanca, ES)
CNS PROPHYLAXIS IN TESTICULAR LYMPHOMAS
E. Zucca (Bellinzona, CH)
PROPHYLAXIS IN LYMPHOMAS – WHAT NEEDS HAVE TO BE FULFILLED?
M. Glantz (Salt Lake City, USA)

Wednesday, June 04, 2008 19:00-20.30 (room B II)

SANOFI AVENITIS
OVERVIEW OF SANOFI-AVENTIC DRUG DEVELOPMENTS IN THE FIELD OF LYMPHOMA
Co-chairs: F. Cavalli (Bellinzona, CH) and M.J. Hallek (Cologne, DE)
SANOFI-AVENTIS PORTFOLIO IN HEMATOLOGY
J. Maral (Paris, FR)
REVISITING ALVOCIDIB IN CLL
T. Lin (Columbus, USA)
EVALUATING OXALIPLATIN IN NHL
C. Haioun (Creteil, FR)
REVERSING ANGIOGENESIS IN NHL, WITH AFLIBERCEPT (VEGF-TRAP)
G. Salles (Pierre Bénite, FR)
REVIEWING RECENT DATA WITH RASBURICASE
A. Younes (Houston, USA)
Wednesday, June 04, 2008 19:00-21:00 (Marquee Parco Ciani)

BING CENTER FOR WALDENSTRÖM'S MACROGLOBULINEMIA
UPDATE ON PLASMA CELL DISORDERS
Chair: S.P. Treon (Boston, USA)

THE ROLE OF NOVEL AGENTS IN THE MANAGEMENT OF MULTIPLE MYELOMA
M. Dimopoulos (Athens, GR)

NATURAL HISTORY AND MANAGEMENT OF MGUS
E. Morra (Milan, Italy)

ADVANCEMENT IN THE DIAGNOSIS TREATMENT OF AMYLOID
G. Merlini (Pavia, Italy)

NOVEL INSIGHTS INTO THE PATHOGENESIS AND TREATMENT OF WALDENSTRÖM'S MACROGLOBULINEMIA
S.P. Treon (Boston, USA)

Thursday, June 05 19:00-21:00 (room A)

BAYER SCHERING PHARMA
A GUIDING LIGHT: ILLUMINATING CURRENT TREATMENT CONCEPTS IN CLL AND T-NHL
Co-chairs: M. Hallek (Cologne, DE) and M.J. Keating (Houston, USA)

ANTI-CD52 ANTIBODY TREATMENT: A GUIDING LIGHT TO IMPROVED PATIENTS OUTCOMES
M.J Keating (Houston, USA)

ENLIGHTENING TREATMENTS IN CLL: PROLONGING SURVIVAL IN HIGH-RISK PATIENTS
S. Stilgenbauer (Ulm, DE)

CONSOLIDATION WITH ANTIBODY THERAPY: CLOSER TO FULL DISEASE ERADICATION
M. Hallek (Cologne, DE)

ADVANCES IN THE TREATMENT OF T-NHL: THE ROLE OF ANTI-CD52 ANTIBODY THERAPY
F. d’Amore (Aarhus, DK)
Thursday, June 05 19:00-21:00 (room B)

CELGENE
LENALIDOMIDE: AN EMERGING OPTION IN HAEMATOLOGICAL MALIGNANCIES
Chair: R. Fonseca (Scottsdale, USA)

LENALIDOMIDE: THE OPTIMAL CHOICE IN NEWLY DIAGNOSED MULTIPLE MYELOMA
A. Palumbo (Turin, IT)

CHOOSING THE BEST STRATEGY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
E. Stadtmauer (Philadelphia, USA)

LENALIDOMIDE IN PRACTICE: EXPERTS’ SOLUTIONS TO CLINICAL QUERIES
Moderator: R. Fonseca (Scottsdale, USA)
A. Palumbo (Turin, IT) and E. Stadtmauer (Philadelphia, USA)

LOOKING FORWARD IN NON-HODGKIN’S LYMPHOMA: LENALIDOMIDE TREATMENT
B. Coiffier (Lyon, FR)

TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA WITH LENALIDOMIDE
A. Ferrajoli (Houston, USA)

Thursday, June 05 19:00-21:00 (Marquee Parco Ciani)

GENENTECH BIOONCOLOGY
ON THE TRAIL TO EFFICIENT CELL DEATH IN B-CELL MALIGNANCIES
Chair: D.G. Maloney (Seattle, USA)

ANTI-CD20 ANTIBODIES WITH INCREASED ANTIGEN BINDING AFFINITY AND ENHANCED EFFECTOR FUNCTION
H. Lowman (South San Francisco, USA)

PHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF B-CELL SPECIFIC ANTIGENS: DOES TARGETING THEM MODU-
LATE DISEASE?
D.G. Maloney (Seattle, USA)

TARGETING TRAIL DEATH RECEPTORS IN LYMPHOMA
A. Younes (Houston, USA)

IMMUNOTHERAPY OF LYMPHOMA
R. Levy (Palo Alto, USA)

ANGIOGENIC MEDIATORS SUPPORT GROWTH AND METASTASIS IN MYELOMA AND LYMPHOMA
J.P. Leonard (New York, USA)
MILLENNIUM PHARMACEUTICALS ORTHO BIOTECH, A DIVISION OF JANSSEN-CILAG
EMERGING THERAPIES FOR RELAPSED AND REFRACTORY LYMPHOID NEOPLASMS

THERAPY FOR RELAPSED AND REFRACTORY LYMPHOID NEOPLASMS
Moderator: P.J. Rosen (Los Angeles, USA)

INTRODUCTION
P.J. Rosen (Los Angeles, USA)

DIFFUSE LARGE B-CELL LYMPHOMA
M. Pfreundschuh (Homburg, DE)

MULTIPLE MYELOMA
P. Leif Bergsagel (Scottsdale, USA)

MANTLE CELL LYMPHOMA
A.H. Goy (Hackensack, USA)

FOLLICULAR LYMPHOMA
A. Hagenbeek (Amsterdam, NL)

BAYER SCHERING PHARMA
RADIO-LABELED IMMUNOTHERAPY: SETTING NEW STANDARDS IN NHL
Co-chairs: M. Ghielmini (Bellinzona, CH) and C. Gisselbrecht (Paris, FR)

CURRENT TREATMENT PARADIGMS FOR FOLLICULAR LYMPHOMA
M. Dreyling (Munich, DE)

RADIO-LABELED IMMUNOTHERAPY: A NEW BENCHMARK FOR FIRST-LINE CONSOLIDATION
G. Salles (Pierre Bénite, FR)

INTEGRATED RADIO-LABELED IMMUNOTHERAPY AND AUTO-SCT IN NHL
C. Gisselbrecht (Paris, FR)

RIsing to the CHALLENGE of AGGRESSIVE LYMPHOMA: IS THERE a ROLE FOR RADIO-LABELED IMMUNOTHERAPY?
P.L. Zinzani (Bologna, IT)